MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ
13.89
-0.50
-3.47%
After Hours: 13.82 -0.07 -0.50% 18:26 05/15 EDT
OPEN
14.30
PREV CLOSE
14.39
HIGH
14.40
LOW
13.63
VOLUME
737.32K
TURNOVER
--
52 WEEK HIGH
35.34
52 WEEK LOW
12.12
MARKET CAP
847.07M
P/E (TTM)
-7.5419
1D
5D
1M
3M
1Y
5Y
1D
Janux VP Accounting Maria Dobek sells 2,038 shares worth $28,874.46
PUBT · 2d ago
Janux Therapeutics price target lowered to $22 from $23 at Evercore ISI
TipRanks · 4d ago
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
TipRanks · 4d ago
Weekly Report: what happened at JANX last week (0504-0508)?
Weekly Report · 4d ago
Janux Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 05/08 15:17
Janux Therapeutics Price Target Cut to $26.00/Share From $30.00 by Piper Sandler
Dow Jones · 05/08 15:17
Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26
Benzinga · 05/08 15:07
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Rocket Pharmaceuticals (RCKT) and Evolent Health (EVH)
TipRanks · 05/08 15:00
More
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.

Webull offers Janux Therapeutics Inc stock information, including NASDAQ: JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.